Bristol Signs Two Cancer Immunotherapy Partners With Eye On Combos
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol will pay $50 million upfront to use CytomX’s Probody platform for up to four cancer immunotherapy targets. The company also partnered with InCyte to study its PD-1 inhibitor nivolumab with Incyte’s oral indoleamine dioxygenase-1 inhibitor.
You may also be interested in...
Third Rock Leads $30 Mil. Series B For CytomX
The startup, which develops antibodies designed to act selectively on diseased tissue, has two preclinical oncology programs.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.
CinFina Pushes Early Work In Obesity In Hopes Of A Deal
Emerging Company Profile: CinFina is advancing two novel mechanisms of action in obesity as monotherapies and in combination with GLP-1s.